Consistent with this observation, the cotreatment group demonstrated the most significant reduction in CD8+, PD-1+, TIM3+, and TOX+ exhausted T cells (Fig. 6e), indicating enhanced activity of tumor-infiltrated CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.